Oral antiviral therapy (nirmatrelvir/ritonavir or Paxlovid) is now available in Quebec for selected patients who are at high risk of progression to severe disease AND identified early (<5days) after onset of symptoms.. Beware drug-drug interactions and limited supply - our latest guidelines offer an approach for outpatient management of COVID-19 for vulnerable high-risk patients. Enjoy!
top of page
Search
Recent Posts
See AllThe ASP committee is happy to give you an early Christmas gift! We published the guidelines on management and treatment of Staphylococcus aureus bacteremia. The diagnostic and antibiotic choice are di
400
ASP committee developed a post-exposure prophylaxis (HIV, hepB & hepC) guidelines in collaboration with the CVIS team. It is available on our website! Francois Bourdeau ASP MUHC coordinator
210
The ASP committee updated the COVID guidelines. You will find the following change: -Removal of the pre-exposure prophylaxis guidelines since monoclonal antibodies are no longer easly available. -Clar
450
bottom of page